JP2006507270A5 - - Google Patents

Download PDF

Info

Publication number
JP2006507270A5
JP2006507270A5 JP2004545186A JP2004545186A JP2006507270A5 JP 2006507270 A5 JP2006507270 A5 JP 2006507270A5 JP 2004545186 A JP2004545186 A JP 2004545186A JP 2004545186 A JP2004545186 A JP 2004545186A JP 2006507270 A5 JP2006507270 A5 JP 2006507270A5
Authority
JP
Japan
Prior art keywords
composition
beta
gastrointestinal
infection
microbial infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004545186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006507270A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/003455 external-priority patent/WO2004035008A2/en
Publication of JP2006507270A publication Critical patent/JP2006507270A/ja
Publication of JP2006507270A5 publication Critical patent/JP2006507270A5/ja
Pending legal-status Critical Current

Links

JP2004545186A 2002-02-06 2003-02-06 感染症および他の疾患の治療 Pending JP2006507270A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35425002P 2002-02-06 2002-02-06
US42103802P 2002-10-25 2002-10-25
PCT/US2003/003455 WO2004035008A2 (en) 2002-02-06 2003-02-06 Treatment of infections and other disorders

Publications (2)

Publication Number Publication Date
JP2006507270A JP2006507270A (ja) 2006-03-02
JP2006507270A5 true JP2006507270A5 (https=) 2006-04-13

Family

ID=32109894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004545186A Pending JP2006507270A (ja) 2002-02-06 2003-02-06 感染症および他の疾患の治療

Country Status (6)

Country Link
US (2) US20060089310A1 (https=)
EP (2) EP2266595A3 (https=)
JP (1) JP2006507270A (https=)
AU (1) AU2003296875B2 (https=)
CA (1) CA2475053A1 (https=)
WO (1) WO2004035008A2 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076254A2 (en) * 2005-01-11 2006-07-20 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing respiratory microbial infection of respiratory tissue
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
EP1755661B1 (en) * 2004-05-12 2014-03-12 The Brigham And Women's Hospital, Inc. Gelsolin for use in treating infections
AU2011218617B2 (en) * 2004-05-12 2014-09-04 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat infections
KR100716119B1 (ko) * 2005-10-24 2007-05-10 (주)케어젠 모발 성장을 촉진하는 펩티드 및 이를 이용한 화장품
ES2641879T3 (es) 2006-03-15 2017-11-14 The Brigham And Women's Hospital, Inc. Uso de gelsolina para diagnosticar y tratar enfermedades inflamatorias
HUE035980T2 (hu) 2006-03-15 2018-06-28 Brigham & Womens Hospital Inc Gelzolin alkalmazása szklerózis multiplex kezelésére és neurológiai betegségek diagnosztizálására
EP2076277A4 (en) * 2006-10-06 2011-06-01 Regenerx Biopharmaceuticals A METHOD FOR TREATING OR PREVENTING DETERIORATION, DAMAGE OR TISSUE DAMAGE DUE TO ORAL MUCOSAL DISEASE OR DISORDER AND / OR REGULATING NF-KAPPAB FALL OR REMOVING NF-KAPPAB ASSISTED ACTIONS
WO2009033690A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Bfgf (119-126) for therapeutic applications
RU2010114005A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение сочетания пептидов тимозина бета4 и индуцирующего дельта-сон пептида в качестве терапевтического средства
DK2250280T3 (en) 2008-01-25 2015-03-09 Gen Hospital Corp THERAPEUTIC USES OF gelsolin in renal failure
JP2011514383A (ja) * 2008-03-17 2011-05-06 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 改良されたベータチモシンフラグメント
US20110160144A1 (en) * 2009-12-28 2011-06-30 Perricone Nicholas V Topical Acyl Glutathione Formulations
US8609604B2 (en) 2009-12-28 2013-12-17 N.V. Perricone Llc Methods of improving the appearance of aging skin
US8580742B2 (en) 2010-03-05 2013-11-12 N.V. Perricone Llc Topical glutathione formulations for menopausal skin
WO2012006667A1 (en) * 2010-07-14 2012-01-19 Adistem Ltd Method of treatment of hiv or aids
CN103724422B (zh) * 2014-01-13 2015-10-21 哈尔滨吉象隆生物技术有限公司 一种裂解胸腺素β4的方法
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
WO2016065075A1 (en) 2014-10-21 2016-04-28 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297276A (en) * 1979-03-23 1981-10-27 Hoffman-La Roche Inc. Thymosin beta 3 and beta 4
CA2156735A1 (en) * 1993-02-22 1994-09-01 Ulrich-Christoph Von Arnim Pharmaceutical compositions for the treatment of inflammatory or immunological diseases and a method for the treatment of said diseases
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
AU766826B2 (en) * 1998-07-30 2003-10-23 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Thymosin beta4 promotes wound repair
EP1169537B1 (en) * 1999-04-14 2004-09-22 Southco, Inc. Crescent hinge
WO2003020215A2 (en) * 2001-08-29 2003-03-13 Regenerx Biopharmaceuticals, Inc. Methods of treating mycocardial event related coditions with thymosin beta 4
KR102632066B1 (ko) 2015-07-30 2024-02-02 가부시키가이샤 한도오따이 에네루기 켄큐쇼 발광 장치의 제작 방법, 발광 장치, 모듈, 및 전자 기기

Similar Documents

Publication Publication Date Title
JP2006507270A5 (https=)
AU2018202201B2 (en) Peptides and their use
ES2565564T3 (es) Una composición que comprende un antibiótico y un dispersante
Langoth et al. Thiolated Chitosans: Design and In Vivo Evaluation of a Mucoadhesive Buccal Peptide Drug Delivery System: Langoth et al.
JP4511173B2 (ja) 抗菌性および抗炎症性ペプチド
DK1739178T3 (da) Levering af trekløverpeptider
EP1718325B1 (en) Treatment of bacterial infections
AU2003296875A1 (en) Treatment of infections and other disorders
WO2003015809A9 (en) Antimicrobial cationic peptides and formulations thereof
CA2513567A1 (en) Cop 1 for treatment of inflammatory bowel diseases
AU2013229486B2 (en) Antimicrobial peptides
US20040152624A1 (en) Oral lactoferrin in the treatment of sepsis
JP2018531880A5 (https=)
JP2020138968A (ja) インフルエンザ後の細菌重感染を処置するための方法及び医薬組成物
JP2009500045A5 (https=)
WO2018037408A1 (en) Antimicrobial peptides and uses thereof
JP2004534084A5 (https=)
JPS61186327A (ja) 感染防禦剤
JP4554150B2 (ja) 薬剤耐性菌による感染症治療剤
CN101247721B (zh) 包括酪蛋白衍生肽的药物组合物及其使用方法
BR0112035A (pt) peptìdeos antimicrobianos de novispirin
CN101342187B (zh) 一种治疗痢疾的药物组合物
BRPI0710846A2 (pt) composto de peptìdeo com atividade biológica, sua preparação e suas aplicações
JP2009502810A5 (https=)
US20220133699A1 (en) Antibacterial Compositions